Bob D. Brown
Dicerna Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
RNA Interference and Gene Delivery, RNA Research and Splicing, RNA modifications and cancer, Advanced biosensing and bioanalysis techniques, Cancer Research and Treatments
Most-Cited Works
- → bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice(1998)487 cited
- → Localization of specific mRNAs in Xenopus embryos by whole-mount in situ hybridization(1990)324 cited
- → RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade(2018)121 cited
- → Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors.(2015)116 cited
- → Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria(2018)104 cited
- → Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1(2016)82 cited
- → Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease(2007)80 cited
- → Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin(2016)61 cited
- → Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo(2013)57 cited
- → Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts(2007)56 cited